BDX vs IMA · P/E 34, rev $21.84B vs rev $9.2M
Becton Dickinson and Company (BDX) versus ImageneBio, Inc. (IMA) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
ImageneBio, Inc. (IMA) is a biotechnology company listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported IMA revenue for 2023-12-31 was $9.2M. Net income was -$68.2M. Revenue was down 41.3% from 2022-12-31 to 2023-12-31. IMA currently screens at market cap $64.7M.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. IMA currently screens at market cap $64.7M.
Not investment advice. Open the BDX and IMA stock pages for the full models.
Not investment advice.